Literature DB >> 32880830

Detection and characterisation of novel alternative splicing variants of the mitochondrial folate enzyme MTHFD2.

Vicky Nicolaidou1, Christos Papaneophytou1, Costas Koufaris2.   

Abstract

Through the process of alternative splicing, proteins with distinct biological functions and localisations are generated from a single gene. The mitochondrial folate metabolism enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) has been receiving attention in recent years as one of the most frequently upregulated metabolic enzymes across multiple tumour types. We hypothesized that alternative splicing of MTHFD2 could be a mechanism that generates novel isoforms of this enzyme, with potentially distinct and important biological functions. Multiple alternatively spliced MTHFD2 transcripts were first characterized in the UCSC and Ensemble genome browser. Subsequently, investigating the transcriptomic data for the Genotype-Tissue Expression (GTeX) project it was found that beyond the canonical MTHFD2 transcript, alternative transcripts lacking the second exon of MTHFD2 are also common. The presence of MTHFD2 transcripts lacking the second exon was confirmed by RT-PCR in normal and cancer cells. Translation of MTHFD2 transcripts lacking this second exon are predicted to generate a truncated protein lacking the first 102 N-terminal amino acids of the full-length protein, including the mitochondrial transport sequence. Hence, the truncated MTHFD2 protein could be an isoform with distinct localisation and functions. However, we were not able to confirm the generation of a stable truncated MTHFD2 protein in eukaryotic cells. This study characterizes for the first time alternative spliced transcripts of the enzyme MTHFD2, although further work is required to investigate their biological significance.

Entities:  

Keywords:  Folate; Isoform; MTHFD2; Mitochondria; Nucleus; Splicing

Mesh:

Substances:

Year:  2020        PMID: 32880830     DOI: 10.1007/s11033-020-05775-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  21 in total

Review 1.  Serine and one-carbon metabolism in cancer.

Authors:  Ming Yang; Karen H Vousden
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

2.  Systematic integration of molecular profiles identifies miR-22 as a regulator of lipid and folate metabolism in breast cancer cells.

Authors:  C Koufaris; G N Valbuena; Y Pomyen; G D Tredwell; E Nevedomskaya; C-He Lau; T Yang; A Benito; J K Ellis; H C Keun
Journal:  Oncogene       Date:  2015-10-19       Impact factor: 9.867

3.  Mitochondrial MTHFD isozymes display distinct expression, regulation, and association with cancer.

Authors:  R Nilsson; V Nicolaidou; C Koufaris
Journal:  Gene       Date:  2019-08-01       Impact factor: 3.688

4.  Suppression of MTHFD2 in MCF-7 Breast Cancer Cells Increases Glycolysis, Dependency on Exogenous Glycine, and Sensitivity to Folate Depletion.

Authors:  Costas Koufaris; Suchira Gallage; Tianlai Yang; Chung-Ho Lau; Gabriel N Valbuena; Hector C Keun
Journal:  J Proteome Res       Date:  2016-07-22       Impact factor: 4.466

5.  MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma.

Authors:  Nathanael H Green; Daniel L Galvan; Shawn S Badal; Benny H Chang; Valerie S LeBleu; Jianyin Long; Eric Jonasch; Farhad R Danesh
Journal:  Oncogene       Date:  2019-07-09       Impact factor: 9.867

6.  The folate-coupled enzyme MTHFD2 is a nuclear protein and promotes cell proliferation.

Authors:  Nina Gustafsson Sheppard; Lisa Jarl; Diana Mahadessian; Laura Strittmatter; Angelika Schmidt; Nikhil Madhusudan; Jesper Tegnér; Emma K Lundberg; Anna Asplund; Mohit Jain; Roland Nilsson
Journal:  Sci Rep       Date:  2015-10-13       Impact factor: 4.379

7.  Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer.

Authors:  Roland Nilsson; Mohit Jain; Nikhil Madhusudhan; Nina Gustafsson Sheppard; Laura Strittmatter; Caroline Kampf; Jenny Huang; Anna Asplund; Vamsi K Mootha
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

8.  Targeting MTHFD2 in acute myeloid leukemia.

Authors:  Yana Pikman; Alexandre Puissant; Gabriela Alexe; Andrew Furman; Liying M Chen; Stacey M Frumm; Linda Ross; Nina Fenouille; Christopher F Bassil; Caroline A Lewis; Azucena Ramos; Joshua Gould; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Clary B Clish; Andrew L Kung; Michael T Hemann; Matthew G Vander Heiden; Versha Banerji; Kimberly Stegmaier
Journal:  J Exp Med       Date:  2016-06-20       Impact factor: 14.307

Review 9.  One-carbon metabolism in cancer.

Authors:  Alice C Newman; Oliver D K Maddocks
Journal:  Br J Cancer       Date:  2017-05-04       Impact factor: 7.640

10.  Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.

Authors:  Huai-Qiang Ju; Yun-Xin Lu; Dong-Liang Chen; Zhi-Xiang Zuo; Ze-Xian Liu; Qi-Nian Wu; Hai-Yu Mo; Zi-Xian Wang; De-Shen Wang; Heng-Ying Pu; Zhao-Lei Zeng; Bo Li; Dan Xie; Peng Huang; Mien-Chie Hung; Paul J Chiao; Rui-Hua Xu
Journal:  J Natl Cancer Inst       Date:  2019-06-01       Impact factor: 13.506

View more
  1 in total

1.  Screening key prognostic factors and constructing survival prognostic risk prediction model based on ceRNA network in early lung adenocarcinoma.

Authors:  Juncheng Bai; Xiaochun Zhu; Jintao Zhang; Baila Bulin
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.